MedTrace Logo

The Safety and Efficiency of Propranolol as an Initial Treatment for Pediatric Hemangioma

NCT01908972 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 34

Last updated 2018-12-19

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to determine the safety and efficiency of Propranolol as an initial treatment for pediatric hemangioma.

Conditions

  • Hemangioma

Interventions

DRUG

Prednisolone

2mg/kg/day for 16weeks

DRUG

Propranolol

2mg/kg/day for 16weeks

Sponsors & Collaborators

  • Seoul National University Hospital

    lead OTHER

Principal Investigators

  • Kyung-Duk Park, MD, Ph D · Seoul National University Hospital

  • Tae Hyun Choi, MD, Ph D · Seoul National University Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Max Age
9 Months
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-06-30
Primary Completion
2015-05-31
Completion
2015-05-31

Countries

  • South Korea

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01908972 on ClinicalTrials.gov